Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders





All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other


Tags
Inv. presentation
Quarterly results

Aptinyx Inc. (APTX) Create: Alert

All | News | Filings
Date FiledTypeDescription
07/03/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
05/11/2023 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing  Interact...
05/05/2023 8-K Quarterly results
04/25/2023 8-K Quarterly results
04/18/2023 8-K Quarterly results
03/01/2023 8-K Quarterly results
02/27/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Aptinyx Reports Results from Phase 2 Study of NYX-458 in Cognitive Impairment Associated with Parkinson's Disease and Dementia with Lewy Bodies and Provides Pipeline and Corporate Update"
12/08/2022 8-K Quarterly results
12/01/2022 8-K Quarterly results
11/08/2022 8-K Quarterly results
08/25/2022 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Aptinyx Completes Enrollment in Phase 2 Study of NYX-458 in Cognitive Impairment Associated with Parkinson’ s Disease and Dementia with Lewy Bodies"
08/12/2022 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Aptinyx Reports Results from Phase 2b Study of NYX-2925 in Fibromyalgia"
08/04/2022 8-K Quarterly results
Docs: "Aptinyx Reports Second Quarter 2022 Financial Results and Recent Highlights"
06/10/2022 8-K Quarterly results
05/31/2022 8-K Quarterly results
05/12/2022 8-K Quarterly results
04/19/2022 8-K Other Events  Interactive Data
04/07/2022 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Aptinyx Reports Results from Phase 2b Study of NYX-2925 in Painful Diabetic Peripheral Neuropathy"
03/23/2022 8-K Quarterly results
Docs: "Year Ended December 31, 2021 2020 2021 2020 Collaboration revenue $ — $ — $ 1,000 $ 1,564 Operating expenses Research and development 14,056 6,786 55,444 32,835 General and administrative 5,116 4,775 20,090 19,494 Total operating expenses 19,172 11,561 75,534 52,329 Loss from operations Other income 73 712 Net loss and comprehensive loss $ $ $ $ Net loss per share - basic and diluted $ $ $ $ Weighted average shares outstanding - basic and diluted 67,716 58,882 67,220 48,866 Investor & Media Contact: Patrick Flavin Aptinyx Inc. [email protected] or [email protected]"
02/28/2022 8-K Quarterly results
02/09/2022 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "PROGRAM INDICATION 1Q 2022 2Q 2022 3Q 2022 4Q 2022 1Q 2023 2Q 2023 3Q 2023 4Q 2023 1Q 2024 NYX"
01/03/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "FIRST AMENDMENT TO AMENDED AND RESTATED EMPLOYMENT AGREEMENT This First Amendment to Amended and Restated Employment Agreement is made effective as of January 1, 2022 , by and between Aptinyx, Inc. , and Andrew D. Kidd . WITNESSETH WHEREAS, the Company and the Executive are parties to an Amended and Restated Employment Agreement effective as of the closing of the Company’ s first underwritten public offering of its equity securities pursuant to an effective registration statement under the Securities Act of 1933 ; WHEREAS, the Company and the Executive wish to amend certain provisions of the Employment Agreement to reflect Executive’ s transition into the Company’ s Chief Executive Officer role; WHEREAS, the Executive is entering into this Amendment in consideration and as a condition of h...",
"FIRST AMENDMENT TO AMENDED AND RESTATED EMPLOYMENT AGREEMENT This First Amendment to Amended and Restated Employment Agreement is made effective as of January 1, 2022 , by and between Aptinyx, Inc. , and Norbert G. Riedel, PhD . WITNESSETH WHEREAS, the Company and the Executive are parties to an Amended and Restated Employment Agreement effective as of the closing of the Company’ s first underwritten public offering of its equity securities pursuant to an effective registration statement under the Securities Act of 1933 ; WHEREAS, the Company and the Executive wish to amend certain provisions of the Employment Agreement to reflect Executive’ s transition into the Company’ s Executive Chairman role; WHEREAS, the Executive is entering into this Amendment in consideration and as a condition o..."
11/09/2021 8-K Quarterly results
Docs: "Aptinyx Reports Third Quarter 2021 Financial Results and Recent Highlights"
10/27/2021 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Aptinyx Completes Enrollment in Phase 2b Study of NYX-2925 in Painful Diabetic Peripheral Neuropathy"
10/20/2021 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Aptinyx Appoints Gilmore O’Neill, M.B., M.M.Sc., to Board of Directors"
09/16/2021 8-K Quarterly results
08/10/2021 8-K Quarterly results
06/15/2021 8-K Quarterly results
06/01/2021 8-K Quarterly results
05/13/2021 8-K Quarterly results
05/10/2021 8-K Quarterly results
03/24/2021 8-K Quarterly results
12/16/2020 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Aptinyx Appoints Andy Kidd, M.D., President and Chief Operating Officer"
11/12/2020 8-K Quarterly results
Docs: "Aptinyx Reports Third Quarter 2020 Financial Results and Recent Highlights"
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy